This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...

NewAmsterdam Pharma shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...

NewAmsterdam Pharma's obicetrapib demonstrates strong phase 3 results. Discover why NAMS stock could rise as further studies ...

Santhera Pharmaceuticals gains approval in China for Agamree, the first Duchenne muscular dystrophy therapy available for ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, hope everyone is ...

Scotiabank analyst George Farmer maintained a Buy rating on NewAmsterdam Pharma Company (NAMS – Research Report) today and set a price target ...

In industry parlance, the deal joins a “delivery” company with a “cargo” company — fusing the two key pieces needed to build ...

Dutch clinical-stage drug developer NewAmsterdam Pharma saw its shares close up 41% at $26.19 yesterday on positive research ...

On Dec. 7, Adaptive Biotechnologies presented new data at ASH 2024 showcasing clonoSEQ MRD testing advances and its role in ...

STOCKHOLM--Swedish buyout group EQT led a series B funding extension for Swiss biotech company Noema Pharma. Noema Pharma is developing a pipeline of therapeutics that address central nervous system ...